Charles Schwab Investment Management Inc. Increases Stock Position in Insmed Incorporated (NASDAQ:INSM)

Charles Schwab Investment Management Inc. lifted its position in Insmed Incorporated (NASDAQ:INSM - Free Report) by 7.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,546,607 shares of the biopharmaceutical company's stock after purchasing an additional 102,341 shares during the period. Charles Schwab Investment Management Inc. owned about 0.86% of Insmed worth $106,778,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Vestal Point Capital LP increased its holdings in Insmed by 113.3% in the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company's stock valued at $116,800,000 after buying an additional 850,000 shares in the last quarter. TimesSquare Capital Management LLC purchased a new position in shares of Insmed in the 3rd quarter valued at about $35,322,000. Victory Capital Management Inc. raised its holdings in Insmed by 209.9% in the 3rd quarter. Victory Capital Management Inc. now owns 455,959 shares of the biopharmaceutical company's stock worth $33,285,000 after purchasing an additional 308,819 shares during the period. Westfield Capital Management Co. LP acquired a new position in Insmed in the 3rd quarter worth about $18,377,000. Finally, Eventide Asset Management LLC boosted its position in Insmed by 34.2% during the third quarter. Eventide Asset Management LLC now owns 906,395 shares of the biopharmaceutical company's stock worth $66,167,000 after purchasing an additional 231,210 shares in the last quarter.

Insider Activity at Insmed

In other news, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the sale, the chief executive officer now owns 384,960 shares of the company's stock, valued at approximately $26,885,606.40. The trade was a 4.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Sara Bonstein sold 1,066 shares of the company's stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $63.72, for a total value of $67,925.52. Following the completion of the transaction, the chief financial officer now owns 118,863 shares in the company, valued at $7,573,950.36. This represents a 0.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 550,957 shares of company stock valued at $42,859,028. 4.60% of the stock is owned by company insiders.

Remove Ads

Analyst Ratings Changes

A number of research firms have recently commented on INSM. HC Wainwright restated a "buy" rating and issued a $90.00 price objective on shares of Insmed in a research report on Friday, February 21st. JPMorgan Chase & Co. boosted their price target on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a report on Friday, February 7th. Guggenheim reaffirmed a "buy" rating and set a $101.00 price objective on shares of Insmed in a report on Tuesday, February 25th. Royal Bank of Canada began coverage on shares of Insmed in a research report on Tuesday, February 25th. They issued an "outperform" rating and a $100.00 target price on the stock. Finally, Truist Financial upped their price target on shares of Insmed from $105.00 to $108.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $93.33.

Insmed Price Performance

Shares of INSM stock traded up $0.37 during trading hours on Wednesday, reaching $74.07. The company had a trading volume of 859,194 shares, compared to its average volume of 1,957,455. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91. The company has a market capitalization of $13.41 billion, a price-to-earnings ratio of -13.27 and a beta of 1.28. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The stock has a fifty day moving average of $75.83 and a 200-day moving average of $73.71.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $104.44 million during the quarter, compared to analysts' expectations of $102.31 million. On average, equities analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.